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Defects in mitochondrial DNA often cause neuromuscular pathologies, for which no efﬁcient therapy has
yet been developed. MtDNA targeting nucleic acids might therefore be promising therapeutic candidates.
Nevertheless, mitochondrial gene therapy has never been achieved because DNA molecules can not
penetrate inside mitochondria in vivo. In contrast, some small non-coding RNAs are imported into
mitochondrial matrix, and we recently designed mitochondrial RNA vectors that can be used to address
therapeutic oligoribonucleotides into human mitochondria. Here we describe an approach of carrier-free
targeting of the mitochondrially importable RNA into living human cells. For this purpose, we developed
the protocol of chemical synthesis of oligoribonucleotides conjugated with cholesterol residue through
cleavable covalent bonds. Conjugates containing pH-triggered hydrazone bond were stable during the cell
transfection procedure and rapidly cleaved in acidic endosomal cellular compartments. RNAs conjugated
to cholesterol through a hydrazone bond were characterized by efﬁcient carrier-free cellular uptake and
partial co-localization with mitochondrial network. Moreover, the imported oligoribonucleotide designed
to target a pathogenic point mutation in mitochondrial DNA was able to induce a decrease in the pro-
portion of mutant mitochondrial genomes. This newly developed approach can be useful for a carrier-free
delivery of therapeutic RNA into mitochondria of living human cells.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Small RNA molecules are increasingly used in clinical applica-
tions. RNA-based therapeutics include inhibitors of mRNA trans-
lation, agents of RNA interference, ribozymes and aptamers binding
various molecular targets [1,2]. Recently, we developed mitochon-
drial RNA vectors that can be used to address therapeutic oligor-
ibonucleotides into human mitochondria [3,4]. To date, >250
human diseases, mostly neuromuscular and neurodegenerative,
were shown to be caused by defects inmitochondrial DNA (mtDNA)
[5]. The majority of these mutations are heteroplasmic, meaning
that mtDNA coexists in two forms, wild type and mutated, in the
same cell. The occurrence and severity of pathologic effects depend
on the heteroplasmy level, therefore, the shift in proportionRoentgen, 67084 Strasbourg
Ltd. This is an open access article ubetween two types of mitochondrial genome could restore mito-
chondrial functions [6,7]. Anti-replicative strategy aims to decrease
the heteroplasmy level by targeting into mitochondria the RNA
molecules able to affect the replication of mutant mtDNA. Recently,
we demonstrated that small RNAs containing structural de-
terminants for mitochondrial import (hairpin domains responsible
for RNA mitochondrial targeting) and 20-nucleotide sequence
corresponding to the mutated region of mtDNA, are able to anneal
selectively to the mutated mitochondrial genomes. Capable to
penetrate into mitochondria of cultured human cells, these RNAs
induced a decrease of the proportion of mtDNA bearing pathogenic
mutations [4,8].
A factor that signiﬁcantly limits biomedical application of RNAs
is their inefﬁcient delivery to target cells and tissues due to large
size, negative charge and low stability of the molecules [9]. A
frequently used approach of therapeutic RNA delivery in the com-
plexes with commercial cationic lipids (as, for instance, Lipofect-
amine) had been characterized by high toxicity and inefﬁciency
in vivo and, therefore, is not suitable for therapeutic applicationsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nalized by natural transport mechanisms is a promising approach
to overcome this problem [11].
To decrease the toxicity of cell transfection procedure and create
an approach of targeting various anti-replicative RNAs into living
human cells, we designed conjugates containing a cholesterol
residue. Cholesterol is a natural lipid and an essential structural
component of animal cell membranes, its efﬁciency as a transporter
molecule and low toxicity were demonstrated by several research
groups [12e14]. Nevertheless, cholesterol could stall the mito-
chondrial import of therapeutic anti-replicative RNA due to
attachment to the mitochondrial membranes. To address this
problem, we synthesized RNA molecules conjugated with choles-
terol through biocleavable covalent bonds. These linkages have
been previously used to release drugs under speciﬁc conditions:
cleavage of disulﬁde bonds is triggered by a mildly reducing
intracellular environment; hydrazone bonds are pH-triggered
linkers releasing the drug in acidic conditions of endosomes [15].
Here we describe the synthesis of oligoribonucleotides conjugated
with cholesterol through cleavable covalent bonds and show that
this approach can be used for a carrier-free transfection of human
cells with anti-replicative RNA molecules addressing mtDNA
mutations.
2. Materials and methods
2.1. Chemical compounds
Thiol-Modiﬁer C6 S-S, 50-Aldehyde-Modiﬁer C2, RNA phos-
phoramidites and solid supports for oligoribonucleotide synthesis
were obtained from Glen Research; cholesteryl chloroformate, 6-
aminohexanoic acid, cysteamine, chloroquine diphosphate salt
and FITC isomer I were purchased from SigmaeAldrich; hydrazine
hydrate from Fluka; ATTO 565 N-succinimidyl ester fromATTO-TEC.
Other chemicals were supplied by Merck, Acros and TCI. Solvents
were supplied by Panreac.
2.2. Synthesis of chemical compounds
2.2.1. 6-(Cholesteryloxycarbonylamino)-hexanoic acid (1)
Compound (1) (Fig. 1A, step i) was synthesized as described in
Ref. [16] with modiﬁcations. 6-Aminohexanoic acid (0.9 g,
6.6 mmol) was suspended in dry pyridine (15 ml), then chloro-
trimethylsilane (3.3 ml, 26.4 mmol) was added dropwise at 0 C.
The mixture was stirred until the solution became clear, then
cholesteryl chloroformate (1 g, 2.2 mmol) was added and the re-
action mixture was stirred for 3 h at room temperature. Pyridine
was evaporated under reduced pressure, the residue was dissolved
in dichloromethane (100 ml), washed with 0.7 M hydrochloric acid
(50 ml) and saturated aqueous NaCl (50 ml). The organic phase was
dried under anhydrous Na2SO4 and evaporated under reduced
pressure. The residue was puriﬁed by Silica gel, pore size 60 Å,
230e400 mesh (Sigma) column chromatography (CH2Cl2/EtOH,
0e30%) to obtain (1) with a yield 0.95 g (80%). 1H NMR spectrawere
recorded on a Bruker AV-400 spectrometer with tetramethylsilane
as an internal standard. H1-NMR (400 MHz, CDCl3, d, ppm): 0.69 (s,
3H, H-18/19 cholesterol); 0.87 (d, 3H, H-26/27 cholesterol); 0.89 (d,
3H, H-26/27 cholesterol); 0.93 (d, 3H, H-21 cholesterol); 1.025 (s,
3H, H-18/19 cholesterol); 2.33 (t, 2H, eCH2eCOOH); 3.35 (dd, 2H,
eCH2eNHe); 4.51 (m, 1H, H-3 cholesterol); 4.88 (t, 1H, eNHe); 5.4
(d, 1H, H-6 cholesterol).
2.2.2. Methyl 6-(cholesteryloxycarbonylamino)hexanoate (2)
Compound (1) (0.2 g, 0.37 mmol) was dissolved in dry dichloro-
methane (5 ml), phosphorus trichloride (13 ml, 0.149 mmol) wasadded (Fig.1A step ii), the reactionmixturewas stirred for 3 h under
argon at 50 C, then absolute methanol (1 ml) was added. The
mixture was diluted by dichloromethane (45 ml) and washed with
saturated aqueous NaHCO3 (50 ml) and twice by water (50 ml). The
organic phasewas dried under anhydrousNa2SO4 and evaporated to
oily residue. The product (2) was puriﬁed by Silica gel column
chromatography (CH2Cl2/EtOH, 0e2.5%) (yield 0.165 g, 80%).
H1-NMR (400 MHz, CDCl3, d, ppm): 0.69 (s, 3H, H-18/19
cholesterol); 0.87 (d, 3H, H-26/27 cholesterol); 0.89 (d, 3H, H-26/27
cholesterol); 0.93 (d, 3H, H-21 cholesterol); 1.025 (s, 3H, H-18/19
cholesterol); 2.29 (t, 2H, eCH2eC(O)OCH3); 3.35 (dd, 2H,
eCH2eNHe); 3.65 (s, 3H, eCH2eC(O)OCH3); 4.51 (m, 1H, H-3
cholesterol); 4.88 (t, 1H, eNHe); 5.4 (d, 1H, H-6 cholesterol).
2.2.3. Hydrazine 6-(cholesteryloxycarbonylamino)hexanoate (3)
Hydrazine derivative (3) was synthesized by analogy with [17].
Compound (2) (0.1 g, 0.18 mmol) was dissolved in methanol (5 ml).
Hydrazine monohydrate (1.25 ml, 49 mmol) was added dropwise
(Fig. 1A step iii), and the reaction mixture was left for 8 h at room
temperature. Compound (3) was precipitated in cold water
(100 ml), the precipitate was ﬁltered off, washed with water and
dried (yield, 0.089 g, 89%). H1-NMR (400 MHz, CDCl3, d, ppm): 0.69
(s, 3H, H-18/19 cholesterol); 0.87 (d, 3H, H-26/27 cholesterol); 0.89
(d, 3H, H-26/27 cholesterol); 0.93 (d, 3H, H-21 cholesterol); 1.025 (s,
3H, H-18/19 cholesterol); 2.13 (t, 2H, eCH2eC(O)NHeNH2); 3.35
(dd, 2H, eCH2eNHe); 3.85 (s, 2H, eCH2eC(O)NHeNH2); 4.51 (m,
1H, H-3 cholesterol); 4.88 (t, 1H, eNHe); 5.4 (d, 1H, H-6 choles-
terol); 6.75 (s, H, eCH2eC(O)NHeNH2).
2.2.4. 2-(Pyridyldithio)-ethylamine (4)
Compound (4) (Fig. 1B step i) was synthesized as described in
Ref. [18] with some modiﬁcations. The reaction was kept under
argon atmosphere. Cysteamine (0.23 g, 2 mmol) was dissolved in
methanol (5 ml) and added dropwise to a stirred solution of 2,20-
dipyridyl disulﬁde (0.88 g, 4 mmol) in methanol/acetic acid (1:25;
4 ml). The mixture was stirred at room temperature for 48 h and
then evaporated to oily residue. The product (4) was precipitated
by cold diethyl ether (20 ml), suspension was ﬁltered and the
precipitation step was repeated three times. H1-NMR (400 MHz,
D2O, d, ppm): 3.1 (m, 2H, NH2eCH2eCH2eSe); 3.29 (t, 2H,
NH2eCH2eCH2eSe); 7.3 (m, 1H, 30-H, pyridyl); 7.74 (m, 1H, 40/50-
H, pyridyl); 7.81 (m, 1H, 40/50-H, pyridyl); 8.4 (m, 1H, 60-H,
pyridyl).
2.2.5. Cholesteryl N-[2-(2-pyridyldisulfonyl)ethyl]carbamate (5)
Synthesis of (5) was carried out as described in Ref. [19] with
some modiﬁcations (Fig. 1B step ii). To the cholesteryl chlor-
oformate solution (0.4 g, 0.9 mmol) in dry dichloromethane (4 ml),
were added the suspension of (4) (0.1 g, 0.45 mmol) in dioxane
(2 ml) and triethylamine (0.15 ml, 1.1 mmol). The reaction mixture
was stirred for 48 h under argon at room temperature. After
addition of dichloromethane (20 ml), reaction mixture was washed
twice with saturated aqueous NaHCO3 (20 ml) and water (20 ml).
The organic phase was dried under anhydrous Na2SO4 and evapo-
rated to oily residue. The product (5) was puriﬁed by Silica gel
column chromatography (hexane/ethyl acetate, 0e30%) (yield
0.19 g, 71%). H1-NMR (400MHz, CDCl3, d, ppm): 0.69 (s, 3H, H-18/19
cholesterol); 0.87 (d, 3H, H-26/27 cholesterol); 0.89 (d, 3H, H-26/27
cholesterol); 0.93 (d, 3H, H-21 cholesterol); 1.025 (s, 3H, H-18/19
cholesterol); 2.92 (dd, 2H, eNHeCH2eCH2eSe); 3.44 (m, 2H,
eNHeCH2eCH2eSe): 4.47 (m, 1H, H-3 cholesterol); 4.88 (t, 1H,
eNHe); 5.35 (d, 1H, H-6 cholesterol); 7.1 (m, 1H, 30-H, pyridyl); 7.51
(m, 1H, 40/50-H, pyridyl), 7.59 (m, 1H, 40/50-H, pyridyl); 8.51 (m, 1H,
60-H, pyridyl).
Fig. 1. Synthesis of oligoribonucleotides conjugated with cholesterol through cleavable covalent hydrazone (A) and disulﬁde (B) bonds. Reagents: A, i) (CH3)3SiCl, Py, 4OC; CholOC(O)
Cl, Py, r.t.; H3Oþ; ii) PCl3, CH2Cl2, argon, 50OC; MeOHabs, r.t.; iii) NH2NH2$H2O, MeOH, r.t.; iv) D20H-CHO, 0.1 M NaOAc, pH 5.0/dioxane, r.t.; v) N-D20H-CHO, 0.1 M NaOAc, pH 5.0/
dioxane, r.t.; B. i) (PyS)2, MeOH/AcOH, r.t.; ii) CholOC(O)Cl, CH2Cl2/dioxane/Et3N, argon, r.t.; iii) D20H-SH, dioxane, r.t.; iv) N-D20H-SH, dioxane, r.t. C. Structure of compounds used
for the synthesis.
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Oligoribonucleotide D20H (Fig. 1C) was synthesized on an
automatic DNA/RNA ASM-800 synthesizer (Biosset) at 0.4 mmol
scale using 20-O-TBDMS-protected phosphoramidites and solid
phase phosphoramidite synthesis protocols [20] optimized for the
instrument. Synthesis of 30-amino modiﬁed oligoribonucleotide
(N-D20H) was carried out using 30-PT-Amino-Modiﬁer C6 CPG
(Glen Research). At the ﬁnal step of the synthesis, Thiol-Modiﬁer C6
S-S or 50-Aldehyde-Modiﬁer C2 phosphoramidites were used.
Cleavage of oligoribonucleotides from the support and removal of
20-O-silyl and nucleobase exocyclic amine protecting groups were
carried out as described previously [13].2.4. Synthesis of lipophilic conjugates with hydrazone bond
(D20HcnCh and N-D20HcnCh)
Modiﬁed with 50-Aldehyde-Modiﬁer C2 phosphoramidite oli-
goribonucleotides D20H and N-D20H were incubated in 80% acetic
acid 1 h at room temperature to remove the acetal protecting
group, then oligoribonucleotides were precipitated by addition of
2% NaClO4 in acetone and isolated via preparative electrophoresis
in 12% polyacrylamide/8 M urea gel (acrylamide:N,N0-methyl-
enebisacrylamide 30:0.5, TBE buffer, 10 V/cm) followed by elutionwith 0.3MNaOAc (pH 5.2)/0.1% SDS solution and precipitationwith
ethanol. Puriﬁed oligoribonucleotides D20HeCHO and N-
D20HeCHO were conjugated with compound (3) (Fig. 1A steps iv,
v). For this, the oligoribonucleotides (5 units A260) dissolved in 50 ml
of 0.1 M NaOAc pH 5.0 were mixed with the same volume of (3)
(3 mg, 5.2 mmol) in dioxane and incubated 12 h at room tempera-
ture with permanent stirring. Yield of the products D20HcnCh and
N-D20HcnCh was estimated by gel electrophoresis and ethidium
bromide staining as a ratio between signals corresponding to
product (D20HcnCh or N-D20HcnCh) and initial compound
(D20HeCHO or N-D20HeCHO). Cholesterol-conjugated oligor-
ibonucleotides D20HcnCh and N-D20HcnCh were characterized by
ESI-TOF-MS analysis (theoretical mass 12405.8 Da, measured mass
12405.2 Da) performed by the Proteomics Platform of Esplanade,
Strasbourg, France.2.5. Synthesis of lipophilic conjugates with disulﬁde bond
(D20HssCh and N-D20HssCh)
Modiﬁed with Thiol-Modiﬁer C6 SeS phosphoramidite (Glen
Research) oligonucleotides D20H and N-D20H (5 units A260) were
treated with 50 mM DTT, 25 mM HEPESeNaOH, pH 8.5 at room
temperature for 30 min with permanent stirring, precipitated with
2% NaClO4 in acetone, the pellet was washed with acetone and
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D20H-SH and N-D20H-SH (Fig. 1C) were puriﬁed using Bio-Rad P6
column in 100 mM HEPESeNaOH, pH 8.5, for complete elimination
of DTT.
Compound (5) (2mg, 3.3 mmol) in dioxane (0.2 ml) was added to
50-thiol oligonucleotide and incubated overnight at room temper-
ature with permanent stirring (Fig. 1B steps iii, iv), followed by
precipitation with 2% NaClO4 in acetone. Cholesterol-conjugated
oligoribonucleotides D20HssCh (yield 30%) and N-D20HssCh
(yield 45%) (yields were estimated as described above) were iso-
lated via preparative electrophoresis in 12% polyacrylamide/8 M
urea gel, followed by elution with 0.3 M NaOAc (pH 5.2)/0.1% SDS
solution and precipitationwith ethanol. The puriﬁed D20HssCh and
N-D20HssCh were characterized by ESI-TOF-MS analysis (theoret-
ical mass 12320.4 Da, measured mass 12321.0 Da).
2.6. Synthesis of ﬂuorescently labelled conjugates
Labelling of lipophilic conjugates with ATTO-565 or FITC was
carried out as described previously [21]. Brieﬂy, the conjugate
containing 30-terminal aminolinker (N-D20HssCh or N-D20HcnCh)
(5 units A260) dissolved in 85 ml of 0.1 M HEPESeNaOH, pH 8.5 was
mixed with 15 ml of N-succinimidyl ester of ATTO-565 in dry DMSO
(5 mg/ml); or (N-D20HcnCh) (1 unit A260) in 30 ml of 0.1 M
HEPESeNaOH, pH 8.5 was mixed with 30 ml of FITC dissolved in dry
DMSO (10 mg/ml). Reaction mixture was incubated overnight at
room temperature with permanent stirring. The conjugates were
precipitated with ethanol as Naþ salts.
2.7. Test of the lipophilic conjugates stability
To test the hydrazone bond stability, 100 ng of D20HcnCh con-
jugate was incubated for 2.5, 4, 6, 8 and 24 h at 37 C in 20 mM Na-
acetate buffer pH 4.6; 5.2 or 5.6 or Na-phosphate buffer pH 6.0; 6.6
or 7.4. Stability of D20HssChwas tested in 20mMHepeseNaOH, pH
7.4 containing 5 mM glutathione (GSH) 3 h at 37 C. For complete
reduction of the disulﬁde bond, the conjugate was incubated with
20 mM bemercaptoethanol 15 min at room temperature.
Reaction products were separated on 8 M urea e 12% PAGE (AA/
bisAA 30:0.5), TBE, stained with ethidium bromide and quantiﬁed
using G-box and GeneTools analysis software (Syngene) or Phos-
phorImager (Typhoon-Trio, GE Healthcare).
For native gel electrophoresis, 120 ng of D20HssCh and
D20HcnCh conjugates were loaded on 1% agarose gel (Sigma), TBE,
stained with ethidium bromide and visualized using G-box
(Syngene).
2.8. Cell culture and transfection
Homo sapiens osteosarcoma 143B cells and primary skin ﬁbro-
blasts from a patient, bearing mtDNA point mutation in the ND5
gene (A13514G) at 30% heteroplasmy level [8], were cultivated at
37 C and 5% CO2 in MEM (Sigma) containing 1 g/l glucose, sup-
plemented with 10% foetal calf serum (Gibco), 100 U/ml penicillin,
100 mg/ml streptomycin, uridine (50 mg/l) and fungizone (2.5 mg/l)
(Gibco). For carrier-free transfection with the lipophilic conjugates
labelled with ATTO-565, osteosarcoma 143B cells (2 cm2) were
washed with PBS, Opti-MEM Reduced Serum Medium (Gibco)
containing conjugates at 10e100 nM ﬁnal concentrationwas added
and cell were cultivated 15 h at 37 C and 5% CO2, then the medium
was changed to MEM. Non-conjugated oligoribonucleotide D20H
was used as a control. Transfection procedure did not lead to
detectable decrease of viability of the cells. Efﬁciency of trans-
fection was evaluated by ﬂow cytometry using CyFlow® Space
(Partec). More than 10,000 cells from each sample were analysedusing Flowing Software 2.5.1 (Perttu Terho, Turku Centre for
Biotechnology).
2.9. Fluorescent confocal microscopy
For confocal microscopy, osteosarcoma 143B cells cultivated in
2 cm2 chambers slide (Lab-Tek) were transfected with ATTO-565 or
FITC labelled RNA-cholesterol conjugates. At different time periods
after transfections, living cells were stained with 100 nM Mito-
Tracker Green or Deep Red correspondingly for 30 min at 37 C,
washed and imaged in MEM without red phenol. For chloroquine
treatment, transfected cells were cultivated in MEM containing
100 mM chloroquine for 5 h, then the medium was changed to
MEM. LSM 780 confocal microscope (Zeiss) was used in conjunc-
tion with Zen imaging software and images acquired with a Zeiss
63/1.40 oil immersion objective. The excitation/emission laser
wavelengths were 488 nm (green channel) and 555 nm (red
channel). Images were analysed using ImageJ [22] and MosaicSuit
plugin [23].
2.10. Heteroplasmy test
Patientﬁbroblasts bearingmtDNApointmutation in theND5 gene
(A13514G) at 30% heteroplasmy level were incubated with 70 nM,
150 nM,1 mMand 2 mM (ﬁnal concentration) of D20HcnCh conjugate
for 15 h, cultivated 2 days in MEM, then a second transfection was
performed in the same conditions. Conjugated oligonucleotide HF-
KSS: GGTCTTTACAGTGCTTACTTCTCGAGCCCCCTACAGGGCTCCA with
antireplicative part corresponding to KSS deletion, which was previ-
ously shown to be imported into mitochondria but cannot anneal to
mtDNA [4,24]was used as a control. In various post-transfection time
periods, cellular DNA was isolated, and heteroplasmy level analysis
was performed as described previously [8], using ﬂuorescently
labelled primer 50-FITC-CATACCTCTCACTTCAACCTCC-30 (Euro-
gentec). Brieﬂy, the heteroplasmy level was analysed by restriction
fragment length polymorphism on a 125-bp PCR fragment encom-
passing themutation site,whereA13514GmutationcreatesanHaeIII-
speciﬁc cleavage site. The HaeIII-digested fragments were separated
on a 10% PAGE and quantiﬁed using Typhoon-Trio Imager (GE
Healthcare). ForeachcellularDNAsample, PCRampliﬁcationhasbeen
performed in triplicates, and each PCR reaction has been digested,
separated on a 10% PAGE and quantiﬁed at least twice.
2.11. Statistical analysis
Results of mitochondrial uptake and heteroplasmy test were
statistically processed using the one-way ANOVA, followed by the
Duncan's test, values of p 0.05 (*), p 0.001 (***) were considered
to be statistically signiﬁcant. IBM SPSS software v.22 has been used
for analysis. Data are expressed as mean ± S.D. for at least 3 inde-
pendent experiments.
3. Results
3.1. Lipophilic conjugates of oligoribonucleotides
To establish a carrier-free transfection of human cells with small
RNA molecules, we used an anti-replicative RNA (referred to as
D20H) targeting a point mutation in ND5 gene, previously
demonstrated to be imported into mitochondria and able to
decrease the heteroplasmy level in human cybrid cells and patient
ﬁbroblasts [8]. This small RNA was conjugated with cholesterol
through a biodegradable disulﬁde bond (D20HssCh, Fig. 1). For this,
oligoribonucleotides synthesized according to the phosphor-
amidite method were 50-thiol-modiﬁed and conjugated with
Fig. 3. Hydrazone bond cleavage in D20HcnCh conjugate. A, Structure of D20HcnCh
conjugate and its cleaved form D20H-CHO. B, Gel electrophoresis analysis of the hy-
drolysis products after incubation of the conjugate at various pH during 2.5, 4, 6, 8 and
24 h (as indicated above the panels). Bands corresponding to the full size conjugate
(upper band) and the product of its acid hydrolysis (lower band) are indicated at the
left. C, Quantiﬁcation of the full size conjugate (%, axis Y) depending on pH and the
time of incubation.
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5, Fig. 1B). Since the length of the linker between the RNA and
lipophilic residue signiﬁcantly inﬂuenced the cellular accumulation
of siRNA conjugates [13], we designed a molecule containing 6
carbon atoms, SeS bridge and another two carbon atoms between
50-nucleotide of RNA and cholesterol residue (Fig. 2A). Puriﬁed
lipophilic oligoribonucleotide was analysed by ESI-TOF mass
spectrometry. The calculated molecular weight was in agreement
with the measured value, conﬁrming the structure of the isolated
product.
Cleavage of the SeS bond by glutathione (GSH) treatment can
be detected by separation of molecules bearing or not a choles-
terol residue by denaturating PAGE (Fig. 2B). After 3 h incubation
at 37 in buffer containing 5 mM GSH (corresponding to GSH
concentration in blood), the SeS bond was not signiﬁcantly
cleaved (Fig. 2B). Upon the increase of GSH concentration up to
5 mM (corresponding to GSH concentration in cytosol of
mammalian cells [25]), SeS bond reduction was detected in 50% of
molecules, indicating that the conjugate of oligoribonucleotide
with cholesterol through a disulﬁde bond should be rapidly
cleaved after delivery into cytoplasm.
Another type of biodegradable linker is a hydrazone bond,
which can be cleaved in acidic conditions of certain cellular com-
partments including endosomes [15]. To obtain an optimal balance
between the hydrazone bond lability under acidic conditions and
stability under neutral conditions, we used the combination of an
aromatic aldehyde with an aliphatic acyl hydrazide [15] (Fig. 1A).
We designed a linker containing 2 carbon atoms, hydrazone bridge
and another 6 carbon atoms between 50-nucleotide of RNA and
cholesterol residue (Fig. 3A).
For this, hydrazino 6- (cholesteryloxycarbonylamino) hexanoate
(compound 3, Fig. 1A) was synthesized and conjugated to D20H
RNA. Lability of the resulted hydrazone bond was tested at various
pH conditions, demonstrating that the hydrazone link is stable at
pH 6.6 and above, while at pH 6.0 it was completely cleaved in 24 h.
At more acidic pH (5.6 and below), cholesterol residue was quickly
cut from oligoribonucleotide (50% and 90% of molecules were
hydrolysed in 2.5 h at pH 6 and 5.6 respectively) (Fig. 3). Therefore,
the conjugate of oligoribonucleotide with cholesterol through a
hydrazone bond (referred to as D20HcnCh) should be stable during
the cell transfection procedure (pH 7.4), and then would be cleaved
inside the endosomes, thus facilitating the release and further
mitochondrial import of the RNA moiety.Fig. 2. Cleavage of disulﬁde bond in D20HssCh conjugate in presence of glutathione
(GSH). A, Structure of D20HssCh conjugate and its reduced form D20H-SH. B, Gel
electrophoresis analysis of the conjugate treated with GSH as indicated above the
panel. Quantiﬁcation of the portion of D20ssCh (upper band) expressed as mean ± S.D.
for 3 independent experiments is shown below the lanes.3.2. Cellular uptake of lipophilic conjugates
To detect and quantify the cellular uptake of RNA conjugated
with cholesterol, 30-end of the oligoribonucleotide was labelled
with ﬂuorescent compound ATTO-565. Carrier-free transfection of
cultured human cells was performed by incubation of osteosar-
coma 143B cells with increasing concentrations of RNA conjugated
with cholesterol and a non-conjugated oligoribonucleotide D20H
used as a control. Efﬁciency of transfection was measured using
cytoﬂuorometry (Fig. 4A,B). The data demonstrate that non-
conjugated RNA can not penetrate the cultured human cells. In
the same conditions, cellular delivery of RNA conjugated with
cholesterol through a disulﬁde bond (D20HssCh) was detectable
but rather inefﬁcient, the ﬂuorescence exceeding the maximum
level of cell auto-ﬂuorescence was detected in less than 10% of cells.
In contrast to poor uptake obtained for D20HssCh, D20H RNA
conjugated through a hydrazone bond (D20HcnCh) was rather
efﬁciently internalized by cells. Percentage of transfected cells
reached a plateau of 90 ± 2% after 15 h of incubation with 70 nM
D20HcnCh (Fig. 4C).
Fluorescent confocal microscopy images also demonstrated a
low internalization of D20HssCh molecules and efﬁcient accumu-
lation of D20HcnCh in the cytoplasm of transfected cells (Fig. 5).
To explain the low level of D20HssCh delivery, we tested the
stability of the both conjugates in conditions used for transfection
Fig. 4. Cellular uptake of ATTO-labelled lipophilic conjugates estimated by ﬂow cytometry. A, percentage of ATTO-positive 143B cells in the population after 15 h incubation with
increased concentrations of conjugates (indicated below). Non-conjugated oligoribonucleotide D20H was used as a control. B, an example of ﬂow cytometry analysis, cells were
incubated 15 h with 70 nM ATTO-D20HcnCh (above), ATTO-D20HssCh (middle panel) or ATTO-D20H (lower panel). In dark grey, signal corresponding to auto-ﬂuorescence of non-
transfected cells. C, the percentage of ATTO-positive 143B cells in the population after incubation with 70 nM D20HcnCh during various periods of time (indicated below). More than
ten thousand events were counted in each sample; mean values from three independent experiments are presented.
Fig. 5. Cellular uptake of ATTO-labelled lipophilic conjugates analysed by ﬂuorescent confocal microscopy of 143B cells after 15 h incubation with ATTO-D20HcnCh or ATTO-
D20HssCh as indicated at the left. Mitochondria were stained with MitoTracker Green (indicated above the panel).
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Thus, a cause of a low efﬁcacy of transfection with RNA conjugate
containing disulﬁde bond remained unclear. One could hypothesize
a self-assembling of this conjugate intomicelle-like particles where
cholesterol residue and the linker form hydrophobic core shielded
by water-soluble RNA [26]. This suggestion has been supported by
the comparison of the mobility of both conjugates, D20HssCh andD20HcnCh, in a native agarose gels, demonstrating that an impor-
tant part of the disulﬁde-containing conjugate is present in the
form a slow-migrating compound. In contrast, for the hydrazone-
containing conjugate we detected two bands, corresponding to
monomeric and dimeric forms of D20HcnCh, but no aggregation
into micelle-like particles was observed (Fig. 6). Thus, the ability of
RNA conjugated with cholesterol to form an aggregate clearly
Fig. 6. Aggregation of D20HssCh molecules in native conditions. Agarose gel analysis
of the lipophilic conjugates. 1, DNA ladder, size of fragments is indicated at the left; 2,
D20HssCh; 3, D20HcnCh. Schematic representation of the monomeric and dimeric
RNA conjugates and their aggregation into micelle-like particles is shown at the right.
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section).
Further experiments were performed with cells transfected
with D20HcnCh conjugate.
3.3. Mitochondrial targeting and anti-replicative capacity of D20H
RNA
We used optimized conditions for the carrier-free cell trans-
fection with D20HcnCh conjugate (15 h of incubation with 70 nM
D20HcnCh) to check if the RNA-component of the internalized
conjugate can be targeted to mitochondria. For this, we used
confocal laser scanning microscopy of living 143B cells. D20HcnCh
was labelled with ﬂuorescein (FITC) at 30-end, mitochondrial
network stained by MitoTracker Deep Red, and co-localization of
ﬂuorescent signals had been quantiﬁed and statistically analysed
(Fig. 7). The data clearly show that the FITC-labelled molecules
were partially (13 ± 3% of the cellular pool) addressed to mito-
chondria 20e45 h post-transfection, then the co-localization level
has been signiﬁcantly decreased, probably indicating on the RNA
degradation in the mitochondrial matrix (Fig. 7A, B). Control ex-
periments with FITC only did not demonstrate signiﬁcant co-
localization with mitochondria (1e2%, not shown).
To check the impact of the hydrazone bond cleavage, which was
anticipated to occur in acid conditions inside the endosomes, facil-
itating the release andmitochondrial import of RNA, we treated the
transfected cells with chloroquine, an agent that prevents endo-
somal acidiﬁcation, commonly used to study the role of endosomal
pH in cellular processes [27]. After 5 h of chloroquine treatment, the
level of D20H co-localisation with mitochondria was signiﬁcantly
decreased (Fig. 7). This indicates that the increased endosomal pH,
preventing the D20HcnCh hydrazone bond cleavage, resulted in the
decreased amount of D20H RNA molecules released from the
membrane-bound conjugate with cholesterol and therefore acces-
sible for the mitochondrial targeting.
To prove that the released D20H RNA still possessed the anti-
replicative activity inside the mitochondria, we performed the
carrier-free transfection of patient ﬁbroblasts bearing the patho-
genic point mutation in ND5 gene of mtDNA. In various post-transfection time periods, cellular DNA was isolated, and the pro-
portion between normal and mutant mitochondrial genomes (so
called heteroplasmy level) was measured by cleavage of the PCR
amplicon (Fig. 8). A small but signiﬁcant decrease of the mutant
mtDNA proportion has been detected in the transfected ﬁbroblasts,
but not in the control cells cultivated in the same conditions. The
same shift of heteroplasmy was obtained in ﬁbroblasts transfected
with D20HcnCh conjugate at concentrations 150 nM, 1 mM and
2 mM, indicating that 150 nM concentration of D20HcnCh can be
sufﬁcient for the antireplicative effect. Control conjugated oligo-
nucleotide bearing an antireplicative part corresponding to KSS
deletion, previously shown to be imported into mitochondria but
not capable to anneal to mtDNA [4,24], did not induce a decrease of
the heteroplasmy in the transfected ﬁbroblasts (Fig. 8).
These data indicate that the conjugation with cholesterol
through hydrazone bond can be useful for a carrier-free delivery of
therapeutic anti-replicative RNA into mitochondria of human cells.
4. Discussion
RNA therapeutics is an emerging class of innovative medicine. In
recent years, signiﬁcant progress has been made to overcome some
of the obstacles associated with in vivo delivery of RNA [28]. Lipid
nanoparticles represent one of the most advanced technological
platforms [29], together with the rapidly developing approach of
molecular conjugates, as triple acetyl-galactosamine conjugates and
combination of backbone neutralization with cell-penetrating
peptides [30], or lipophilic conjugates [12,31]. A variety of lipo-
philic moieties can be conjugated to siRNAs to improve the in vivo
uptake, the best studied one is cholesterol. Mechanistically,
cholesterol-modiﬁed siRNAs interact with serum lipoprotein parti-
cles and the uptake is dependent upon cellular lipoprotein and other
transmembrane receptors [12]. Recently reported data demonstrate
that the adsorption of siRNA lipophilic conjugates on the cell surface
and their subsequent transport into the cells could occur via the
mechanism of endocytosis. It was suggested that two main factors
might determine the efﬁcacy of adsorption of the conjugates on the
cell surface: the hydrophobicity of the conjugates and the distance
between negatively charged cellular membrane and anionic siRNA
[13]. The long aliphatic linker in the conjugate structure provides an
optimal distance between the cellularmembrane and siRNAmoiety,
along with an increase of the hydrophobicity of the conjugates.
Taking into account these data, we synthesized mitochondrially
imported RNAs conjugated to cholesterol through the linker con-
taining 8 aliphatic eCH2e units.
Another important point is that chemical modiﬁcations intro-
duced into RNA molecules should not interfere with their sub-
cellular localization and therapeutic function. In case of siRNA du-
plexes, a lipophilic residue can be conjugated to the sense strand,
which is destroyed upon the cell delivery by RISC complex. Anti-
replicative RNAs are expected to be targeted into mitochondrial
matrix and to stall the mutant mitochondrial genomes replication
[4]. The lipophilic cholesterol residue could impede its mitochon-
drial import. In fact, human mitochondria possess a system facili-
tating the transport of cholesterol from the outer mitochondrial
membrane to the inner one. This transport is necessary for
cholesterol metabolization to pregnenolone, the precursor of all
steroid hormones [32]. Translocator protein of the outer mito-
chondrial membrane TSPO consists of ﬁve transmembrane helices
forming a channel-like structure that may accommodate the
import of lipophilic molecules into mitochondria and contains a
recognition motif with high afﬁnity to cholesterol [33]. Therefore,
the cholesterol residue can be recognized by TSPO and translocated
through the outer mitochondrial membrane. In this case, RNA
molecule conjugated with cholesterol would be trapped on the
Fig. 7. Mitochondrial targeting of D20H RNA evaluated by ﬂuorescent confocal microscopy. A, confocal microscopy images of 143B cells incubated with FITC-D20HcnCh (green
signal), 20 h (1), 45 h (2) and 70 h (3) post-transfection; (4), cells were incubated with FITC-D20HcnCh for 15 h, treated with chloroquine for 5 h and analysed 45 h post-transfection.
Mitochondrial network was visualized by MitoTracker DeepRed staining. B, quantiﬁcation of RNA co-localization with mitochondria, estimated as the percentage of green ﬂuo-
rescence signal co-localized with red ﬂuorescence for 6e14 optical sections. The data were statistically processed using the one-way ANOVA, followed by the Duncan's test.
Signiﬁcant differences between cells: *, p < 0.05; ****, p < 0.001.
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chondrial matrix. To avoid this problem, we introduced a cleavable
linker between RNA and cholesterol residue. We expected that the
linkers (disulﬁde or hydrazone bonds) should be stable during cell
transfection procedure and cleaved upon internalizing of the con-
jugate in the cytoplasm [15]. Mammalian cells uptake of extracel-
lular macromolecules proceeds through endocytosis, leading (for
the most of endocytosis pathways) to formation of vesicle-like
structures that fuse with early endosomes characterised by a
reduced pH (6.0e6.6, compared to a physiological pH 7.2e7.4) [34].
The pH drops further during endosomal processing, reaching 5.0 atthe late endosomal stage. Therefore, we supposed that the hydra-
zone bond between RNA and cholesterol moieties would be cleaved
inside the endosome, while the disulﬁde bond should be cleaved
after release of the conjugate into the cytoplasm. In both cases, this
should permit the mitochondrial targeting of the therapeutic RNA.
Unexpectedly, our data revealed a very low level of cellular
uptake for RNA conjugated with cholesterol through a disulﬁde
bond (D20HssCh) compared to RNA conjugated through a hydra-
zone bond (D20HcnCh). The cause of low efﬁcacy of transfection
with RNA conjugate containing disulﬁde bond remains unclear. It
had been demonstrated that siRNAs conjugated through disulﬁde
Fig. 8. The effect of D20HcnCh on the heteroplasmy level in transfected patient ﬁbroblasts bearing A13514G mutation in mtDNA. Time dependence of heteroplasmy level after two
consecutive transfections with various concentrations of D20HcnCh conjugate (indicated below the graphs) or in the control cells cultivated in the same conditions without
transfection. KSS, cells transfected with a control conjugated oligonucleotide which cannot anneal to mtDNA. Data are expressed as mean ± S.D. for 3 independent experiments.
Signiﬁcant differences between control and transfected cells were calculated by one-way ANOVA, followed by Duncan's test (*, p < 0.05).
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cell transfection had not been estimated. As a possible explanation
of a low transfection, we can hypothesize a self-assembling of the
disulﬁde-containing conjugate into micelle-like particles (Fig. 6)
where cholesterol residue and the linker form hydrophobic core
shielded by water-soluble RNA. Soft micellar nanoparticles as-
sembly from DNAecholesterol conjugates have been recently
described [36]. Cholesterol residues shielded inside the particles
could not bind the cell surface receptors and, therefore, penetrate
the cells.
In case of the hydrazone containing conjugate, the ratio between
hydrophobic and hydrophilic parts of the molecule should be more
signiﬁcant than in case of disulﬁde linker. This would prevent the
self-assembling of conjugates into micelle-like particles [26], thus
increasing the amount of molecules available for the cell delivery.
Therefore, the hydrazone containing conjugate D20HcnCh demon-
strated an efﬁcient carrier-free cellular uptake. The level of its
consequent co-localisation with mitochondria was estimated as
13± 3% of the D20H cellular pool (Fig. 7).We suppose that this value
is limited by the endosomal escape of the D20H RNA after the
hydrazone bond cleavage in acidic conditions. However, the treat-
ment of transfected cell with chloroquine, one of the endosomal
escape agents,whichwas supposed to facilitate the disruption of the
endosomalmembrane due to proton spongemechanism [37], in fact
decreased the mitochondrial targeting of D20H RNA (Fig. 7). These
data indicate that the conjugated molecules D20HcnCh were
anchored in the endosomal membranes by the cholesterol residue.
Since the endosomal pH has been increased by the chloroquine
treatment, the hydrazone bond between the cholesterol and RNA
components was not cleaved, and RNA could not be released into
cytoplasm even after the disruption of endosomes.
Noteworthy, the moderate mitochondrial import of D20H RNA
still allowed detection of its anti-replicative activity. Even the small
decrease of heteroplasmy level (Fig. 8) can be important to obtain a
curative effect of mitochondrial dysfunctions in human cells, since
only high levels of mutations in humanmtDNA become pathogenic
[6], while a small reduction of the mutant DNA load can provide
signiﬁcant clinical improvement [38].
The present study was done on cultivated primary ﬁbroblasts
from patients affected by mitochondrial dysfunction and repre-
sents a proof of concept that the biodegradable cholesteroleRNA
conjugates can be used for reducing a level of mtDNA pathologicalmutation. The next step towards the therapy would be to use more
developed models. Concerning ex vivo therapies, our system could
be applied to treatment of speciﬁc tissue of affected patient which
can be cultivated and treated following by re-injection, for instance,
marrow tissue in the case of Pearson marrow-pancreas syndrome,
associated with deletions in mtDNA [39]. Another model would be
the transmitochondrial lines of mice embryonic stem cells carrying
heteroplasmic mtDNA mutations in genes coding for respiratory
subunits or tRNA [40,41]. These ES cells, able to differentiate into
neurons or myoblasts, provide therefore a model to study the
cellular pathophysiology and the effect of the therapeutic RNA
delivery on deﬁned tissue types. Our system could be also applied
to test the possibility of induced heteroplasmy change in embryos
bearing mutations in mtDNA. Recently an alternative approach of
mtDNA cleavage by mitoTALENs has been successfully applied to
mice embryos [42]. Our system could be also tested for the possi-
bility to induce a heteroplasmy change in embryos bearing patho-
genic mutations in mtDNA, which would be helpful for the
preimplantation genetic diagnosis and possible therapy [43].
Only fewmurinemodels carryingmitochondrial DNAmutations
have been described to date, due to difﬁculties in producing
transgenic mice carrying pathogenic mtDNA mutations [44]. Het-
eroplasmic mutations described in transgenic mice include life-
long expanding deletion in mtDNA (“mito-mice”, [45]) or a point
mutation in the tRNALys gene mimicking the MERRF syndrome-
associated mutation [41]. If even it has not be possible to
completely recapitulate, in these murine lines, the human symp-
toms associated with mtDNA defects, the model could be used for
the validation of the antireplicative strategy. To improve the in vivo
delivery of cholesteroleRNA conjugates, we are planning to design
and synthesize conjugated molecules containing various nucleo-
tide and inter-nucleotide modiﬁcations which can improve the
stability of anti-replicative RNA moieties and promote their tissue
distribution and cellular uptake.
5. Conclusion
We have developed an approach of carrier-free targeting of the
mitochondrially importable RNA into living human cells. RNA
conjugated with cholesterol through a hydrazone bond represents
a new type of conjugates containing pH-triggered link. Anti-
replicative RNA conjugated to cholesterol through a hydrazone
I. Dovydenko et al. / Biomaterials 76 (2016) 408e417 417bond was efﬁciently internalized by cells, partially co-localized
with mitochondrial network and induced a decrease in the pro-
portion of mitochondrial genomes bearing a pathogenic point
mutation. We believe that the present study represents a further
step towards the development of RNA therapeutics against incur-
able mitochondrial diseases.
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